@article{article, title  = {{Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation}},

 url = {{}},

 year = {{2016}},

 month = {{11}},

 author = {{Stevenson M and Archer R and Tosh J and Simpson E and Everson-Hock E and Stevens J and Hernandez-Alava M and Paisley S and Dickinson K and Scott D and Young A et al}},

 doi = {{10.3310/hta20350-c201611}},

 volume = {{20}},

 journal = {{Health Technology Assessment}},

 issue = {{35}},

 pages = {{611-614}},

 note = {{Accessed on 2024/10/19}}}